ClinicalTrials.gg
CompletedNCT05376488Updated Feb 13, 2025

Effect of Brief Dietary Intervention on Ammonia Levels

An interventional study of One meal in Cirrhosis and Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.

Primary conditionHepatic EncephalopathyRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatic Encephalopathy
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hepatic Encephalopathy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Study the impact of differing meal contents on venous ammonia levels over time in patients with cirrhosis. Patients will be given specific meals and venous ammonia analyzed over time after those meals.

The subjects will also provide stool for microbiome and serum, urine and plasma for metabolomics during this one-time study.

Total duration=4 hours

Read the detailed description

Patient will be instructed to collect stool for baseline assessments. After a fast (>4h from last meal) a venous blood sample will be drawn for analysis of baseline laboratory tests and spot venous ammonia and blood and urine for metabolomics and blood microbiome. Spot ammonia and blood for metabolomics and microbiome will be collected from repeat samples at 1h and 2 hrs after a standardized meals from the three groups of protein meals. Urine will also be collected for metabolomics during the observation period. On the day of the study, patients will be asked to complete a standard food frequency questionnaire encompassing meals over 3 days prior to the study.

Subjects will be randomly assigned into 3 groups (meal types A, B and C) with the standardized meal that contains 20gm of protein. All subjects are expected to consume it in its entirety. Subjects are not allowed to eat anything else until the end of the study.

Subjects will be observed in the unit for a total of 3 hours after the standardized meal to ensure no symptoms related to potential elevated ammonia emerge. Any adverse events will be treated according to standard clinical routine.

02

Conditions studied

  • Cirrhosis
  • Hepatic Encephalopathy

Browse trials for

03

In context

Hepatic Encephalopathy Reclassified

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.

Browse Hepatic Encephalopathy studies →

Lead sponsor

Hunter Holmes Mcguire Veteran Affairs Medical Center is the lead sponsor of 31 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Compared within Hepatic Encephalopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cirrhosis
  2. Able and willing to voluntarily complete the process
  3. Available for and agree to all study procedures
  4. Consistent non-vegetarian Western dietary patterns for at least a month prior to the study assessed by dietary interview

Exclusion criteria

Exclusion Criteria:

  1. MELD score > 23
  2. Unclear diagnosis of cirrhosis
  3. History of liver transplant
  4. \< 18.5 or ≥ 40 kg/m2
  5. Prior transjugular intrahepatic portosystemic shunt placement
  6. Treatment with systemic (e.g., oral or intravenous) antibiotic (apart from rifaximin) within 4 weeks prior to enrollment
  7. For those with HE: stable dose of medications (lactulose or rifaximin) without a recent (\<1 month episode of HE)
  8. Current use of valproate, , or cytotoxic drugs.
  9. Apart from chronic liver disease, any acute or chronic medical, surgical, psychiatric, or social condition including history of cerebrovascular disease (stroke, ) or dementia, that may increase the subject risk associated with study participation, compromise adherence to study procedures and requirements, confound interpretation of the results, and, in the judgment of the investigator, make the subject inappropriate for enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Meal type A

    Meal type A: equicaloric meal as meal type B and C with differing constituents

    Other: One meal

  • Active comparator
    Meal type B

    Meal type B: equicaloric meal as meal type A and C with differing constituents

    Other: One meal

  • Experimental
    Meal type C

    Meal type C: equicaloric meal as meal type B and A with differing constituents

    Other: One meal

Interventions

  • OtherOne meal

    One meal given to assess impact on ammonia levels serially

06

What researchers measure

Primary outcomes

  1. Venous ammonia level

    Change in these levels hourly from baseline

    Time frame: 3 hours

Secondary outcomes

  1. Venous ammonia level

    Change in these levels from baseline to hour 1

    Time frame: 1 hour

  2. Venous ammonia level

    Change in these levels from baseline to hour 2

    Time frame: 2 hours

  3. Venous ammonia level

    Change in these levels from baseline to hour 3

    Time frame: 3 hours

07

Study locations

1 site
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05376488
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Responsible party
Sponsor
First posted
May 17, 2022
Start date
May 1, 2022
Primary completion
Dec 20, 2022
Completion
Apr 20, 2023
Last update
Feb 13, 2025

Study contacts

Jasmohan Bajaj
principal investigator · Hunter Holmes McGuire VAMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion